9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following High-Risk Exposure

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Non-pharmaceutical interventions (NPIs) are recommended for COVID-19 prevention. However, the effectiveness of NPIs in preventing SARS-CoV-2 transmission remains poorly quantified.

          Methods

          We conducted a test-negative design case-control study enrolling cases (testing positive for SARS-CoV-2) and controls (testing negative) with molecular SARS-CoV-2 diagnostic test results reported to California Department of Public Health between 24 February–12 November, 2021. We used conditional logistic regression to estimate adjusted odds ratios (aORs) of case status among participants who reported contact with an individual known or suspected to have been infected with SARS-CoV-2 (“high-risk exposure”) ≤14 days before testing.

          Results

          751 of 1448 cases (52%) and 255 of 1443 controls (18%) reported high-risk exposures ≤14 days before testing. Adjusted odds of case status were 3.02-fold (95% confidence interval: 1.75–5.22) higher when high-risk exposures occurred with household members (vs. other contacts), 2.10-fold (1.05–4.21) higher when exposures occurred indoors (vs. outdoors only), and 2.15-fold (1.27–3.67) higher when exposures lasted ≥3 hours (vs. shorter durations) among unvaccinated and partially-vaccinated individuals; excess risk associated with such exposures was mitigated among fully-vaccinated individuals. Cases were less likely than controls to report mask usage during high-risk exposures (aOR = 0.50 [0.29–0.85]). The adjusted odds of case status was lower for fully-vaccinated (aOR = 0.25 [0.15–0.43]) participants compared to unvaccinated participants. Benefits of mask usage were greatest among unvaccinated and partially-vaccinated participants, and in interactions involving non-household contacts or interactions occurring without physical contact.

          Conclusions

          NPIs reduced the likelihood of SARS-CoV-2 infection following high-risk exposure. Vaccine effectiveness was substantial for partially and fully vaccinated persons.

          Abstract

          SARS CoV-2 infection risk was greatest for unvaccinated participants when known or suspected exposures to cases occurred indoors or lasted ≥3 hours. Face mask usage when participants were exposed to a case reduced odds of infection by 50%.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

          Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines against this variant has been unclear. Methods We used a test-negative case–control design to estimate the effectiveness of vaccination against symptomatic disease caused by the delta variant or the predominant strain (B.1.1.7, or alpha variant) over the period that the delta variant began circulating. Variants were identified with the use of sequencing and on the basis of the spike ( S ) gene status. Data on all symptomatic sequenced cases of Covid-19 in England were used to estimate the proportion of cases with either variant according to the patients’ vaccination status. Results Effectiveness after one dose of vaccine (BNT162b2 or ChAdOx1 nCoV-19) was notably lower among persons with the delta variant (30.7%; 95% confidence interval [CI], 25.2 to 35.7) than among those with the alpha variant (48.7%; 95% CI, 45.5 to 51.7); the results were similar for both vaccines. With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among persons with the alpha variant and 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant. With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among persons with the alpha variant and 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant. Conclusions Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses. Absolute differences in vaccine effectiveness were more marked after the receipt of the first dose. This finding would support efforts to maximize vaccine uptake with two doses among vulnerable populations. (Funded by Public Health England.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

            Abstract Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel’s largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine. Methods All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics. Study outcomes included documented infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), symptomatic Covid-19, Covid-19–related hospitalization, severe illness, and death. We estimated vaccine effectiveness for each outcome as one minus the risk ratio, using the Kaplan–Meier estimator. Results Each study group included 596,618 persons. Estimated vaccine effectiveness for the study outcomes at days 14 through 20 after the first dose and at 7 or more days after the second dose was as follows: for documented infection, 46% (95% confidence interval [CI], 40 to 51) and 92% (95% CI, 88 to 95); for symptomatic Covid-19, 57% (95% CI, 50 to 63) and 94% (95% CI, 87 to 98); for hospitalization, 74% (95% CI, 56 to 86) and 87% (95% CI, 55 to 100); and for severe disease, 62% (95% CI, 39 to 80) and 92% (95% CI, 75 to 100), respectively. Estimated effectiveness in preventing death from Covid-19 was 72% (95% CI, 19 to 100) for days 14 through 20 after the first dose. Estimated effectiveness in specific subpopulations assessed for documented infection and symptomatic Covid-19 was consistent across age groups, with potentially slightly lower effectiveness in persons with multiple coexisting conditions. Conclusions This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Respiratory virus shedding in exhaled breath and efficacy of face masks

              We identified seasonal human coronaviruses, influenza viruses and rhinoviruses in exhaled breath and coughs of children and adults with acute respiratory illness. Surgical face masks significantly reduced detection of influenza virus RNA in respiratory droplets and coronavirus RNA in aerosols, with a trend toward reduced detection of coronavirus RNA in respiratory droplets. Our results indicate that surgical face masks could prevent transmission of human coronaviruses and influenza viruses from symptomatic individuals.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Infect Dis
                Clin Infect Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                21 December 2021
                21 December 2021
                : ciab1040
                Affiliations
                Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley , California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                California Department of Public Health , Richmond, California, USA
                Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley , California, USA
                Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley , California, USA
                Center for Computational Biology, College of Engineering, University of California, Berkeley , California, USA
                Author notes
                Correspondence: J. A. Lewnard, 2121 Berkeley Way, Berkeley, CA 94720 ( jlewnard@ 123456berkeley.edu ).

                K. L. A. and J. P. contributed equally to the study.

                S. J. and J. A. L. contributed equally to the study.

                Members of the California COVID-19 Case-Control Study Team are listed in the Acknowledgments section.

                Article
                ciab1040
                10.1093/cid/ciab1040
                8903328
                34932817
                391ad59f-778f-49b5-9883-a3bc59bb7ef9
                © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

                This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                : 20 October 2021
                : 11 December 2021
                : 09 February 2022
                Page count
                Pages: 13
                Funding
                Funded by: California Department of Public Health, DOI 10.13039/100005002;
                Award ID: 5-NU50CK000539
                Funded by: Epidemiology & Laboratory Capacity for Infectious Diseases;
                Funded by: Centers for Disease Control and Prevention, DOI 10.13039/100000030;
                Award ID: 0187.0150
                Award ID: R01-AI14812701
                Funded by: National Institute of Allergy and Infectious Diseases, DOI 10.13039/100000060;
                Categories
                Major Article
                AcademicSubjects/MED00290
                Custom metadata
                PAP
                corrected-proof

                Infectious disease & Microbiology
                sars-cov-2,non-pharmaceutical interventions,face masks,vaccination

                Comments

                Comment on this article